Pneumonic Plague: The Darker Side of Yersinia pestis

Trends in Microbiology

Volumn 24, Issue 3, 2016, Pages 190-197

  Pechous, Roger D ^a   Sivaraman, Vijay ^b   Stasulli, Nikolas M ^a   Goldman, William E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

Plague; Pneumonic plague; Yersinia pestis

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; UNCLASSIFIED DRUG; YERSINIA PESTIS VACCINE; BIOLOGICAL WARFARE AGENT;

AEROSOL; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE AGENT; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; EPIDEMIC; HOST PATHOGEN INTERACTION; HUMAN; INNATE IMMUNITY; LETHALITY; LIFE THREAT; MEDICAL HISTORY; MORTALITY; NONHUMAN; PATHOGENESIS; PLAGUE; PNEUMONIC PLAGUE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; YERSINIA PESTIS; ANIMAL; GROWTH, DEVELOPMENT AND AGING; LUNG; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PATHOPHYSIOLOGY; TRANSMISSION; VIRULENCE;

ANIMALS; BIOLOGICAL WARFARE AGENTS; DISEASE PROGRESSION; HUMANS; LUNG; PLAGUE; VIRULENCE; YERSINIA PESTIS;

EID: 84958770552     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2015.11.008     Document Type: Review

References (60)

1. Achtman M., et al. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:14043-14048.
2. Rasmussen S., et al. Early divergent strains of Yersinia pestis in Eurasia 5,000 years ago. Cell 2015, 163:571-582.
3. Perry R.D., Fetherston J.D. Yersinia pestis - etiologic agent of plague. Clin. Microbiol. Rev. 1997, 10:35-66.
4. Darling R.G., et al. Threats in bioterrorism. I: CDC category A agents. Emerg. Med. Clin. North Am. 2002, 20:273-309.
5. Weant K.A., et al. Being prepared: bioterrorism and mass prophylaxis: part I. Adv. Emerg. Nurs. J. 2014, 36:226-238.
6. Tieh T.H., Landauer E. Primary pneumonic plague in Mukden, 1946, and report of 39 cases with three recoveries. J. Infect. Dis. 1948, 82:52-58.
7. Ratsitorahina M., et al. Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar. Lancet 2000, 355:111-113.
8. Inglesby T.V., et al. Plague as a biological weapon: medical and public health management. JAMA 2000, 283:2281-2290.
9. Galimand M., et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N. Engl. J. Med. 1997, 337:677-680.
10. Guiyoule A., et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg. Infect. Dis. 2001, 7:43-48.
11. Riedel S. Plague: from natural disease to bioterrorism. Proc. (Bayl. Univ. Med. Cent.) 2005, 18:116-124.
12. Stenseth N.C., et al. Plague: past, present, and future. PLoS Med. 2008, 5:e3.
13. Ligon B.L. Plague: a review of its history and potential as a biological weapon. Semin. Pediatr. Infect. Dis. 2006, 17:161-170.
14. Slack P. The black death past and present. 2. Some historical problems. Trans. R. Soc. Trop. Med. Hyg. 1989, 83:461-463.
15. Keim P.S., Wagner D.M. Humans and evolutionary and ecological forces shaped the phylogeography of recently emerged diseases. Nat. Rev. Microbiol. 2009, 7:813-821.
16. Butler T. Plague gives surprises in the first decade of the 21st century in the United States and worldwide. Am. J. Trop. Med. Hyg. 2013, 89:788-793.
17. Schrag S.J., Wiener P. Emerging infectious disease: what are the relative roles of ecology and evolution?. Trends Ecol. Evol. 1995, 10:319-324.
18. Duplantier J-M., et al. From the recent lessons of the Malagasy foci towards a global understanding of the factors involved in plague reemergence. Vet. Res. 2005, 36:437-453.
19. McGovern T.W., et al. Cutaneous manifestations of biological warfare and related threat agents. Arch. Dermatol. 1999, 135:311-322.
20. Williams P., Wallace D. Unit 731: Japan's Secret Biological Warfare in World War II 1989, The Free Press.
21. Zilinskas R.A. The anti-plague system and the Soviet biological warfare program. Crit. Rev. Microbiol. 2006, 32:47-64.
22. Finegold M.J. Pneumonic plague in monkeys. An electron microscopic study. Am. J. Pathol. 1969, 54:167-185.
23. Bubeck S.S., et al. Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect. Immun. 2007, 75:697-705.
24. Agar S.L., et al. Characterization of a mouse model of plague after aerosolization of Yersinia pestis CO92. Microbiology 2008, 154:1939-1948.
25. Agar S.L., et al. Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92. Microbes Infect. 2009, 11:205-214.
26. Lathem W.W., et al. Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17786-17791.
27. Lathem W.W., et al. A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 2007, 315:509-513.
28. Vagima Y., et al. Early sensing of Yersinia pestis airway infection by bone marrow cells. Front. Cell Infect. Microbiol. 2012, 2:143.
29. Vagima Y., et al. Circumventing Y. pestis virulence by early recruitment of neutrophils to the lungs during pneumonic plague. PLoS Pathog. 2015, 11:e1004893.
30. Sivaraman V., et al. Yersinia pestis activates both IL-1β and IL-1 receptor antagonist to modulate lung inflammation during pneumonic plague. PLoS Pathog. 2015, 11:e1004688.
31. Pechous R.D., et al. Early host cell targets of Yersinia pestis during primary pneumonic plague. PLoS Pathog. 2013, 9:e1003679.
32. Pechous R.D., et al. In vivo transcriptional profiling of Yersinia pestis reveals a novel bacterial mediator of pulmonary inflammation. MBio 2015, 6:e02302-e2314.
33. Laws T.R., et al. Neutrophils are important in early control of lung infection by Yersinia pestis. Microbes Infect. 2010, 12:331-335.
34. Li B., et al. Use of protein microarray to identify gene expression changes of Yersinia pestis at different temperatures. Can. J. Microbiol. 2011, 57:287-294.
35. Han Y., et al. Microarray analysis of temperature-induced transcriptome of Yersinia pestis. Microbiol. Immunol. 2004, 48:791-805.
36. Montminy S.W., et al. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat. Immunol. 2006, 7:1066-1073.
37. Price P.A., et al. Pulmonary infection by Yersinia pestis rapidly establishes a permissive environment for microbial proliferation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3083-3088.
38. Peters K.N., et al. Early apoptosis of macrophages modulated by injection of Yersinia pestis YopK promotes progression of primary pneumonic plague. PLoS Pathog. 2013, 9:e1003324.
39. Cantwell A.M., et al. YopH inhibits early pro-inflammatory cytokine responses during plague pneumonia. BMC Immunol. 2010, 11:29.
40. Stasulli N.M., et al. Spatially distinct neutrophil responses within the inflammatory lesions of pneumonic plague. MBio 2015, 6:e01530-e1615.
41. Zimbler D.L., et al. Early emergence of Yersinia pestis as a severe respiratory pathogen. Nat. Commun. 2015, 6:7487.
42. Welkos S.L., et al. Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092. Microb. Pathog. 1997, 23:211-223.
43. Sodeinde O.A., et al. A surface protease and the invasive character of plague. Science 1992, 258:1004-1007.
44. Caulfield A.J., et al. The Pla protease of Yersinia pestis degrades Fas ligand to manipulate host cell death and inflammation. Cell Host Microbe 2014, 15:424-434.
45. Eddy J.L., et al. Impact of the Pla protease substrate α2-antiplasmin on the progression of primary pneumonic plague. Infect. Immun. 2015, 83:4837-4847.
46. Ponnusamy D., et al. High-throughput, signature-tagged mutagenic approach to identify novel virulence factors of Yersinia pestis CO92 in a mouse model of infection. Infect. Immun. 2015, 83:2065-2081.
47. Lathem W.W., et al. Posttranscriptional regulation of the Yersinia pestis cyclic AMP receptor protein Crp and impact on virulence. MBio 2014, 5:e01038-e1113.
48. Williamson E.D., Oyston P.C.F. The natural history and incidence of Yersinia pestis and prospects for vaccination. J. Med. Microbiol. 2012, 61:911-918.
49. Russell P., et al. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 1995, 13:1551-1556.
50. Leary S.E., et al. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect. Immun. 1995, 63:2854-2858.
51. Meyer K.F. Effectiveness of live or killed plague vaccines in man. Bull. World Health Organ. 1970, 42:653-666.
52. Quenee L.E., et al. Hereditary hemochromatosis restores the virulence of plague vaccine strains. J. Infect. Dis. 2012, 206:1050-1058.
53. Frank K.M., et al. Investigation of a researcher's death due to septicemic plague. N. Engl. J. Med. 2011, 364:2563-2564.
54. Tiner B.L., et al. Intramuscular immunization of mice with a live-attenuated triple mutant of Yersinia pestis CO92 induces robust humoral and cell-mediated immunity to completely protect animals against pneumonic plague. Clin. Vaccine Immunol. 2015, 10.1128/CVI. 00499-15.
55. Williamson E.D., et al. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague. Vaccine 2011, 29:4771-4777.
56. Davis K.J., et al. Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops). Arch. Pathol. Lab. Med. 1996, 120:156-163.
57. Quenee L.E., et al. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines. Vaccine 2011, 29:6572-6583.
58. Jones S.M., et al. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 2003, 21:3912-3918.
59. Williamson E.D., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect. Immun. 2005, 73:3598-3608.
60. Eisele N.A., Anderson D.M. Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague. Clin. Vaccine Immunol. 2009, 16:1720-1727.